Loading clinical trials...

COMPLETEDNA

The Effect of a Weight Management Program During Treatment With Olanzapine

The Effect of a Weight Management Program to Prevent Weight Gain and Metabolic Abnormalities During Treatment With the Atypical Neuroleptic Olanzapine: A Randomised Study

NCT00169702•Heinrich-Heine University, Duesseldorf

View on ClinicalTrials.gov

Summary

The study is a prospective, randomized, open-label study.

Detailed Description

The principal objective of this trial is to investigate the effect of a comprehensive behavioural treatment program on weight gain in schizophrenic patients under olanzapine treatment, and on subjective well-being.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia
•Ages between 18 and 65
•Informed consent
•Weight gain of at least 1.5 kg in the first 4 weeks
•A sufficient understanding to participate adequately in the weight management program
•Patients must agree to cooperate with all tests and examinations required by the protocol.
•Each patient must understand the nature of the study and must sign an informed consent document.

Exclusion Criteria

•Serious, unstable somatic illnesses
•Illnesses associated with weight gain including renal and endocrine diseases
•Weight change greater than 3 kg in the preceding three months
•Weight gain less than 1.5 kg in the first 4 weeks

Locations (1)

Heinrich-Heine-University, Rhineland State Clinics Düsseldorf

Düsseldorf, Rhineland State, Germany

Key Dates

Start Date

June 1, 2003

Completion Date

July 1, 2007

Last Updated

January 30, 2008

Enrollment

100

ACTUAL participants

Conditions

Schizophrenia

Interventions

weight management program

BEHAVIORAL

weight management program

BEHAVIORAL

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITING

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383

Schizophrenia Spectrum and Other Psychotic DisordersSchizophrenia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 30, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effect of a Weight Management Program During Treatment With Olanzapine

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques

Brain Stimulation to the Hippocampus in Schizophrenia